In this report, the global human insulin market is segmented on the basis of basis of products (human insulin biologics, insulin analogs & biosimilars, and delivery devices), drug type (rapid-acting, intermediate-acting, long-acting, short-acting, and premixed), drug brand (Lantus, NovoRapid/Novolog, Humalog, Humulin, Insuman, Actrapid,
Insulatard, Mixtard, and Other Biosimilar Brands), delivery devices [insulin pens (reusable & disposable), pen needles (standard & safety), and conventional syringes], and applications (type I diabetes & type II diabetes).
Patients were randomly assigned to receive NPH insulin at bedtime (
Insulatard; Novo Nordisk, Copenhagen, Denmark) in addition to current treatment with sulfonylurea and metformin (insulin combination [IC] group) or to receive a mixture of 30% soluble and 70% NPH insulin (Mixtard 30/70; Novo Nordisk, Copenhagen, Denmark), twice daily before breakfast and dinner (insulin monotherapy [IM] group).